• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up0.25% Nasdaq Up0.65%

    StemCells Inc. (STEM)

    3.03 Up 0.06(2.02%) May 27, 4:00PM EDT
    ProfileGet Profile for:
    StemCells Inc.
    7707 Gateway Boulevard
    Suite 140
    Newark, CA 94560
    United States - Map
    Phone: 510-456-4000
    Fax: 510-456-4001
    Website: http://www.stemcellsinc.com

    Index Membership:N/A
    Full Time Employees:74

    Business Summary 

    StemCells, Inc., a biopharmaceutical company, engages in the research, development, and commercialization of cell-based therapeutics and related technologies. It develops HuCNS-SC platform technology, a purified human neural stem cells used as a potential therapeutic to treat diseases and disorders of the central nervous system. The company’s HuCNS-SC is in Phase I clinical trials for the treatment of Pelizeaus-Merzbacher Disease; and has completed a Phase I clinical trial for infantile and late infantile neuronal ceroid lipofuscinosis. Its HuCNS-SC is also in Phase I/II clinical trials for the treatment of thoracic spinal cord injury; Phase II clinical trials for the treatment of cervical spinal cord injury; and Phase I/II clinical trials for dry age-related macular degeneration. StemCells, Inc. was founded in 1988 and is headquartered in Newark, California.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on StemCells Inc.

    Key Executives 
    Dr. Ian John Massey D.Phil, 65
    Chief Exec. Officer, Pres and Director
    Mr. Gregory T. Schiffman MBA, CPA, 59
    Chief Financial Officer and Exec. VP of Fin.
    Mr. Kenneth B. Stratton J.D., Esq., 47
    Gen. Counsel and Sec.
    Mr. Martin M. McGlynn , 70
    Dr. Ann Tsukamoto Ph.D., 63
    Exec. VP of Scientific & Strategic Alliances
    Amounts are as of Dec 31, 2015 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.
    View Insiders